Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

2023 FDA approvals

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 23, 88-95 (2024)


Updates & Corrections

  • Update 22 January 2024: Information on the financial performance of the new drugs approved and the characteristics of the reviews by the FDA has been added to the article, with an additional column in Table 1 and Figure 4.

  • Correction 22 March 2024: Daiichi Sankyo has been added as one of the companies sponsoring the development of patritumab deruxtecan in Table 4.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links